• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1998 Fiscal Year Final Research Report Summary

High-dose chemotherapy with a support of autologous stem cell transplantation in advanced and refractory ovarian cancer.

Research Project

Project/Area Number 08671932
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionTokai University

Principal Investigator

SHINOZUKA Takao  Tokai Univ.School of Med.Associate Professor., 医学部, 助教授 (30110901)

Co-Investigator(Kenkyū-buntansha) OSAMURA Yoshiyuki  Tokai Univ.School of Med.Professor, 医学部, 教授 (10100992)
MURAMATSU Toshinari  Tokai Univ.School of Med.Instructor, 医学部, 助手 (90266437)
MIYAMOTO Tsuyosi  Tokai Univ.School of Med.Instructor, 医学部, 助手 (60209947)
MURAKAMI Masaru  Tokai Univ.School of Med.Assistant Professor, 医学部, 講師 (00190893)
Project Period (FY) 1996 – 1998
Keywordsovarian carcinoma / high-dose chemotherapy / autologous bone marrow transplantation / prognostic factor / long-term follow up
Research Abstract

BACKGROUND.Next results were obtained by high dose chemotherapy(HDC) with autologous bone marrow transplantation in advanced and refractory ovarian cancer.
PATIENTS AND METHODS.After maximum debulking surgery of the 105 epithelial ovarian cancer patients, HDC with stem cell support was given composed of cyclophosphamide 1600-2400 mg/m^2 adriamycin 80-100 mg/m^2+ cisplatin 100-150 mg/m^2(n=58), or carboplatin 900-1500 mg/m^2+ cyclophosphamide 3000 mg/m^2. ABMT or PBSCT were performed 48 hours or 72 hours after HDC, respectively.
RESULTS.Five- and 8-years overall survivals(OS) by FIGO stage were I c(n13) : 92.3%.92.3%, II (n=12) : 73.3%.73.3%, LII (n=46) : 58.1%.48.8%, lV(n=19) : 33.7%. 33.7% , relapsedlrefractory(n=15) : 37.5%.37.5% , and disease free survival(DFS) were I c : 92.3%.92.3%, II : 73.3%.73.3%, III : 35.7%.31.7%, IV : 22.6%.22.6% , relapsedlrefractory : 31.0%.31.0%. In 65 stage 1III/V patients, 5-year OS accordinng to the residual tumor size before performing HDC were 0-0.5 cm (n=35) : 74.3%, 0.6-2 cm(n=13) : 30.8%, >2 cm(n=17) : 22.6%. Best results of long long term survival were obtained in 35 patients with small volume residual disease(0-0.5cm). Histologically, patients with mucinous and clear cell adenocarcinoma showed significantly worse long term survivals than other histologies.
FUTURE STRATEGY.For better long term survivals, we are now planning HDC with peripheral blood stem cell transplantation containg multi drugs including pacitaxel, which sensitive for epithelial ovarian cancers.

  • Research Products

    (16 results)

All Other

All Publications (16 results)

  • [Publications] 篠塚 孝男 他: "卵巣癌大療化学療法における骨髄抑制に対する末梢血幹細胞移植法の効果" Oncology & Chemotherapy. 12. 107-112 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 篠塚 孝男 他: "末梢血幹細胞移植・G-CSF併用による進行卵巣癌の治療" Oncology & Chemotherapy. 13. 83-86 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 篠塚 孝男 他: "超大量化学療法" 癌の臨床 臨時増刊号. 43. 1391-1400 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 篠塚 孝男 他: "婦人科癌の最新治療動向 特集. 卵巣癌の最新治療動向 : 新しい化学療法〜高濃度化学療法の意義(PBSCTを主に)〜" 癌治療と宿主. 10. 50-56 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 篠塚 孝男 他: "表層上皮性卵巣悪性腫瘍での治療成績(特集 婦人科癌に対する造血幹細胞移植)" Oncology & Chemotherapy. 14. 227-231 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Shinozuka T, et al.: "High-dose chemotherapy with autologous stem cell support in patients. with ovarian cancer : Long-term results of 105 patients." Cancer.(in press.). (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 篠塚 孝男: "婦人科がん治療学-4. 卵巣癌. D薬物療法" 金原出版(株), 野田 起一朗 監修 野澤 茂朗, 大川 智彦 編集., 426 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 篠塚 孝男: "新臨床外科学(第3版)-4. 婦人科腫瘍" (印刷中),

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Shinozuka T,et al.: "Efficacy of peripheral blood stem cell transplantation in high dose chemotherapy against ovarian cancer." Oncology and Chemotherapy. 12. 107-112 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T,et al.: "Peripheral blood stem cell transplantation in combination with G-CSF administration in the treatment of advanced ovarian cancer." Oncology and Chemotherapy. 13. 83-86 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T,et al.: "Ultra-high dose chemotherapy." JP J Cancer Clinic. 43. 1391-1400 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T,et al.: "New approach for the treatment of ovarian cancer-high dose chemotherapy with peripheral blood stem cell transplantation." Cancer Therapy & Host. 10. 50-56 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T,et al.: "Results of high dose chemotherapy with hematopoietic stem cell support in epithelial ovarian cancer." Oncology and Chemotherapy. 14. 227-231 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T,et al.: "High-dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma." Long-term results for 105 patients.Cancer. (in press.). (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T.: Chemotherapy.In : Nozawa S,Ookawa T,eds.Therapeutics in Gynecological Cancers : Ovarian cancer. Tokyo : Kanehara & Co LTD., 426 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinozuka T.: Gynecologic tumor.In : New Clinical Surgery. Tokyo : Igakushoin ; in press., (1999)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-12-08  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi